Chiesi and Protalix Secure CHMP Nod for Extended Dosing Regimen of Elfabrio in Fabry Disease

Event summary

  • CHMP issued a positive opinion for a 2mg/kg every-4-weeks dosing regimen of pegunigalsidase alfa (Elfabrio) for Fabry disease, following a re-examination.
  • European Commission decision expected by March 2026; approval would reduce treatment burden for adult patients.
  • Protalix eligible for a $25 million regulatory milestone payment from Chiesi upon EC approval.
  • Opinion based on results from the BRIGHT study and its ongoing extension study CLI-06657AA1-03.

The big picture

The CHMP's positive opinion for an extended dosing regimen of Elfabrio aligns with broader industry trends toward patient-centric treatment solutions in rare diseases. This development could set a precedent for other enzyme replacement therapies, emphasizing the importance of reducing treatment burden. The strategic partnership between Chiesi and Protalix underscores the growing collaboration in biopharmaceutical innovation, particularly in addressing unmet needs in rare disease treatment.

What we're watching

Regulatory Approval
Whether the European Commission will approve the CHMP's positive opinion by March 2026, enabling the extended dosing regimen for Elfabrio.
Commercial Impact
How the reduced treatment burden could enhance patient compliance and market adoption of Elfabrio in the EU.
Financial Milestone
The potential $25 million regulatory milestone payment to Protalix, contingent on EC approval, and its impact on the company's financials.